CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


metenkefalin + tridecactideWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug2494 The standard of care Wiki 1.00
drug1853 Placebo oral tablet Wiki 0.19
drug1086 Hydroxychloroquine Wiki 0.10

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D003141 Communicable Diseases NIH 0.09
D007239 Infection NIH 0.06

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 An Open-label, Prospective, Randomized, Comparative Clinical Trial to Evaluate the Efficacy and Safety of ENKORTEN® as an Immunomodulatory Therapy, Within the Usual Therapeutically Established Protocol, for the Treatment of Patients With Moderate to Severe COVID-19 Infection

An Open-label, prospective, randomized, comparative, multiple doses applied in addition to the standard of care treatment of patients with moderate to severe COVID-19 infection

NCT04374032 COVID-19 Infection Drug: metenkefalin + tridecactide Drug: The standard of care
MeSH:Infection Communicable Diseases

Primary Outcomes

Description: The time of onset of improvement in the patient's clinical condition will be measured following the clinical objective and subjective signs and radiological indicators.

Measure: Time to onset of change in the patient's clinical condition

Time: 21 day

Description: At every examination/evaluation, all AEs, whether noticed by investigators and their associates in the trial, or spontaneously reported by the subjects, or given as answer to direct question, must be evaluated by the investigator and reported on case report forms for AE. AE will be recorded in the e-CRF. Three-degree scale will be used for assessment of AE's severity: mild, moderate, severe.

Measure: Safety and tolerability evaluation - treatment-related adverse events will be assessed by CTCAE

Time: 21 day

Secondary Outcomes

Description: To monitor the period of patient's hospitalization

Measure: Length of in-hospital stay

Time: 21 day

Description: To monitor the survival rate during the hospitalization

Measure: Survival rate

Time: 21 day

Description: To monitor the intubation frequency during the hospitalization

Measure: Intubation rate

Time: 21 day

Description: To monitor the levels of proinflammatory markers during the hospitalization (IL-6)

Measure: Proinflammatory markers levels

Time: 21 day


No related HPO nodes (Using clinical trials)